Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State’s High Rate of Lung Cancer
January 30 2020 - 9:00AM
Business Wire
Florida has a rate of 59.3 per 100,000 new lung
cancer cases compared to the national rate of 59.6.
In an effort to show how
advances in science are being harnessed in the fight against lung
cancer, The LungXperience, an educational exhibit sponsored by
AstraZeneca, will be making a stop at The Villages Balloon
Festival. The free exhibit, designed to help educate the public
about lung cancer, will be at The Villages Polo Club on February 7
from 2 PM to 9 PM and February 8 from 2 PM to 9 PM.
“Florida is home to many
prominent medical institutions and research facilities dedicated to
public health and the fight against cancer. It’s a mission of great
importance to us,” said State Senator Dennis Baxley (R-District
12). “Given the high rate of lung cancer in Florida and need for
greater public education to fight this disease together, this
innovative exhibit will give Floridians an opportunity to look at
lung cancer in a new way.”
Among Floridians with lung cancer, nearly half (48.5%) of
diagnoses are not discovered until a later stage when survival is
lower. In 2020, AstraZeneca has expanded The LungXperience national
roadshow, traveling to cities like The Villages that have higher
incidences of lung cancer.
“Lung cancer is one of the most prevalent and deadly cancers
today. Early detection and intervention can save lives. Getting a
screening is not only a wise thing to do, it might just be the
determining factor between life and death,” said State
Representative Ralph Massullo, MD (R-District 34).
The LungXperience is a 14-foot
tall by 9-foot wide giant
inflatable lung equipped with five augmented reality modules that
take visitors through a narrative, from the stages of lung cancer
to the role of biomarkers, and the latest medical advances. To
activate the interactive modules, visitors are each given an iPad
equipped with an augmented reality app and a pair of
noise-cancelling headphones for the immersive experience. Visitors
to The LungXperience receive take-home brochures and postcards that
provide additional information and resources.
“The LungXperience provides an
interactive and immersive experience to educate the public about a
serious topic – lung cancer – and to show how medical advances are
changing what it means to be diagnosed with this disease,” said
Chatrick Paul, Head of US Oncology, AstraZeneca. “Today, thanks to
advancing science, there are more therapeutic options available so
that those diagnosed may live longer with the disease. We hope that
after visiting the exhibit, people have the information they need
to engage in a more informed conversation with their
doctor.”
For more information about lung cancer and The LungXperience
exhibit, visit https://lungxperience.com/, where visitors can
follow the roadshow as it makes its way across the US and download
the experience to view at home.
NOTES TO EDITORS
About The LungXperience
The LungXperience is a traveling, interactive exhibit created by
AstraZeneca to educate people about the newest advances in the
science of treating lung cancer. The LungXperience exhibit features
an inflatable lung that allows participants to walk through the
lung using a smartphone or iPad and activate five interactive
education modules. The exhibit will cover a range of lung cancer
topics including the staging of the disease, potential treatment
options and what the future of care might look like. The exhibit is
traveling to cities around the US for display in community events,
such as awareness walks and health festivals.
About Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer death among both men
and women, accounting for about one-fifth of all cancer deaths in
the US, more than breast, prostate and colorectal cancers
combined.
About AstraZeneca in Lung Cancer
AstraZeneca is committed to developing medicines to help every
patient with lung cancer. We have three approved medicines and a
growing pipeline that targets genetic changes in tumor cells and
boosts the power of the immune response against cancer. Our
unrelenting pursuit of science aims to deliver more breakthrough
therapies with the goal of extending and improving the lives of
patients across all stages of disease and lines of therapy.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a
quickly growing portfolio of new medicines that has the potential
to transform patients' lives and the Company's future. With at
least six new medicines to be launched between 2014 and 2020, and a
broad pipeline of small molecules and biologics in development, we
are committed to advance Oncology as a key growth platform for
AstraZeneca focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative
partnerships and investments that accelerate the delivery of our
strategy, as illustrated by our investment in Acerta Pharma in
hematology.
By harnessing the power of four scientific platforms –
Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates – and by championing the development
of personalized combinations, AstraZeneca has the vision to
redefine cancer treatment and one day eliminate cancer as a cause
of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three therapy areas – Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
US-36290 Last Updated 1/20
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005033/en/
Michele Meixell +1 302 885 2677 Stephanie Wiswall +1 302 885
2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024